Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 | Synapse
October 17, 2025Open Access
Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Key Points
Adverse effects in over 20% of patients combined camizestrant with CDK4/6 inhibitors.
The study involves women with ER+, HER2− advanced breast cancer receiving treatment.
Analysis of adverse outcomes utilized data from SERENA-1 trial, focusing on AE profiles.
Highlights importance of understanding adverse effects for better therapeutic strategies.
Abstract
AE profile for camizestrant in combination with abemaciclib, palbociclib, or ribociclib (irrespective of causality); AEs reported in ≥20% of patients.a